Antiviral activity of ovine interferon tau 4 against foot-and-mouth disease virus

Antiviral Research

Volumn 143, Issue , 2017, Pages 134-141

  Usharani, Jayaramaiah ^a   Park, Sun Young ^a   Cho, Eun Ju ^a   Kim, Chungsu ^a   Ko, Young Joon ^a   Tark, Dongseob ^b   Kim, Su Mi ^a   Park, Jong Hyeon ^a   Lee, Kwang Nyeong ^a   Lee, Myoung Heon ^a   Lee, Hyang Sim ^a  

^a Ministry of Agriculture and Forestry Korea   (South Korea)

^b Chonbuk National University   (South Korea)

Author keywords

Antiviral agent; Foot and mouth disease virus; Ovine interferon tau 4

Indexed keywords

ANTIVIRUS AGENT; INTERFERON TAU 4; MESSENGER RNA; TAU INTERFERON; UNCLASSIFIED DRUG; INTERFERON; PLACENTA PROTEIN; RECOMBINANT PROTEIN; TROPHOBLAST PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANTIVIRAL ACTIVITY; ARTICLE; CELL PROTECTION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; FOOT AND MOUTH DISEASE; FOOT AND MOUTH DISEASE VIRUS; GENE EXPRESSION; IMMORTALIZED KIDNEY CELL LINE; IN VITRO STUDY; IN VIVO STUDY; INFECTION PREVENTION; LD50; LFBK CELL LINE; MOLECULAR CLONING; MOUSE; NONHUMAN; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SEROTYPE; SHEEP; SUCKLING ANIMAL; SURVIVAL RATE; VIRUS STRAIN; WESTERN BLOTTING; ANIMAL; CELL LINE; DRUG EFFECTS; GENETICS; PATHOGENICITY; VACCINATION;

ANIMALS; ANTIVIRAL AGENTS; CELL LINE; CLONING, MOLECULAR; FOOT-AND-MOUTH DISEASE; FOOT-AND-MOUTH DISEASE VIRUS; GENE EXPRESSION; INTERFERON TYPE I; LETHAL DOSE 50; MICE; PREGNANCY PROTEINS; RECOMBINANT PROTEINS; SHEEP; VACCINATION;

EID: 85018521800     PISSN: 01663542     EISSN: 18729096     Source Type: Journal    
DOI: 10.1016/j.antiviral.2017.01.018     Document Type: Article

References (30)

1. Alexenko, A.P., Ealy, A.D., Roberts, R.M., The cross-species antiviral activities of different IFN-tau subtypes on bovine, murine, and human cells: contradictory evidence for therapeutic potential. J. Interferon Cytokine Res. 19 (1999), 1335–1341.
2. Cummins, J.M., Krakowka, G.S., Thompson, C.G., Systemic effects of interferons after oral administration in animals and humans. Am. J. Vet. Res. 66 (2005), 164–176.
3. Dereuddre-Bosquet, N., Clayette, P., Martin, M., Mabondzo, A., Fretier, P., Gras, G., Martal, J., Dormont, D., Anti-HIV potential of a new interferon, interferon-tau (trophoblastin). J. Acquir Immune Defic. Syndr. Hum. Retrovirol. 11 (1996), 241–246.
4. Diaz-San Segundo, F., Weiss, M., Perez-Martin, E., Koster, M.J., Zhu, J., Grubman, M.J., de los Santos, T., Antiviral activity of bovine type III interferon against foot-and-mouth disease virus. Virology 413 (2011), 283–292.
5. Domingo, E., Escarmis, C., Baranowski, E., Ruiz-Jarabo, C.M., Carrillo, E., Nunez, J.I., Sobrino, F., Evolution of foot-and-mouth disease virus. Virus Res. 91 (2003), 47–63.
6. Grubman, M.J., Baxt, B., Foot-and-mouth disease. Clin. Microbiol. Rev. 17 (2004), 465–493.
7. Johnson, J.A., Hochkeppel, H.K., Gangemi, J.D., IFN-tau exhibits potent suppression of human papillomavirus E6/E7 oncoprotein expression. J. Interferon Cytokine Res. 19 (1999), 1107–1116.
8. Juste, R.A., Ott, T.L., Kwang, J., Bazer, F.W., de La Concha-Bermejillo, A., Effects of recombinant ovine interferon-tau on ovine lentivirus replication and progression of disease. J. Gen. Virol. 81 (2000), 525–532.
9. Kim, S.M., Kim, S.K., Park, J.H., Lee, K.N., Ko, Y.J., Lee, H.S., Seo, M.G., Shin, Y.K., Kim, B., A recombinant adenovirus bicistronically expressing porcine interferon-alpha and interferon-gamma enhances antiviral effects against foot-and-mouth disease virus. Antivir. Res. 104 (2014), 52–58.
10. LaRocco, M., Krug, P.W., Kramer, E., Ahmed, Z., Pacheco, J.M., Duque, H., Baxt, B., Rodriguez, L.L., A continuous bovine kidney cell line constitutively expressing bovine alphavbeta6 integrin has increased susceptibility to foot-and-mouth disease virus. J. Clin. Microbiol. 51 (2013), 1714–1720.
11. Livak, K.J., Schmittgen, T.D., Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) method. Methods 25 (2001), 402–408.
12. Martal, J.L., Chene, N.M., Huynh, L.P., L'Haridon, R.M., Reinaud, P.B., Guillomot, M.W., Charlier, M.A., Charpigny, S.Y., IFN-tau: a novel subtype I IFN1. Structural characteristics, non-ubiquitous expression, structure-function relationships, a pregnancy hormonal embryonic signal and cross-species therapeutic potentialities. Biochimie 80 (1998), 755–777.
13. Moraes, M.P., de Los Santos, T., Koster, M., Turecek, T., Wang, H., Andreyev, V.G., Grubman, M.J., Enhanced antiviral activity against foot-and-mouth disease virus by a combination of type I and II porcine interferons. J. Virol. 81 (2007), 7124–7135.
14. Nakajima, A., Sokawa, Y., Induction of blood 2',5'-oligoadenylate synthetase activity in mice by gastric administration of ovine IFN-tau. J. Interferon Cytokine Res. 22 (2002), 397–402.
15. Oliveira, J.F., Henkes, L.E., Ashley, R.L., Purcell, S.H., Smirnova, N.P., Veeramachaneni, D.N., Anthony, R.V., Hansen, T.R., Expression of interferon (IFN)-stimulated genes in extrauterine tissues during early pregnancy in sheep is the consequence of endocrine IFN-tau release from the uterine vein. Endocrinology 149 (2008), 1252–1259.
16. Ott, T.L., Fleming, J.G., Spencer, T.E., Joyce, M.M., Chen, P., Green, C.N., Zhu, D., Welsh, T.H. Jr., Harms, P.G., Bazer, F.W., Effects of exogenous recombinant ovine interferon tau on circulating concentrations of progesterone, cortisol, luteinizing hormone, and antiviral activity; interestrous interval; rectal temperature; and uterine response to oxytocin in cyclic ewes. Biol. Reprod. 57 (1997), 621–629.
17. Park, J.H., Lee, K.N., Ko, Y.J., Kim, S.M., Lee, H.S., Shin, Y.K., Sohn, H.J., Park, J.Y., Yeh, J.Y., Lee, Y.H., Kim, M.J., Joo, Y.S., Yoon, H., Yoon, S.S., Cho, I.S., Kim, B., Control of foot-and-mouth disease during 2010-2011 epidemic, South Korea. Emerg. Infect. Dis. 19 (2013), 655–659.
18. Platanias, L.C., Mechanisms of type-I- and type-II-interferon-mediated signalling. Nat. Rev. Immunol. 5 (2005), 375–386.
19. Pontzer, C.H., Bazer, F.W., Johnson, H.M., Antiproliferative activity of a pregnancy recognition hormone, ovine trophoblast protein-1. Cancer Res. 51 (1991), 5304–5307.
20. Pontzer, C.H., Ott, T.L., Bazer, F.W., Johnson, H.M., Structure/function studies with interferon tau: evidence for multiple active sites. J. Interferon Res. 14 (1994), 133–141.
21. Pontzer, C.H., Torres, B.A., Vallet, J.L., Bazer, F.W., Johnson, H.M., Antiviral activity of the pregnancy recognition hormone ovine trophoblast protein-1. Biochem. Biophys. Res. Commun. 152 (1988), 801–807.
22. Pontzer, C.H., Yamamoto, J.K., Bazer, F.W., Ott, T.L., Johnson, H.M., Potent anti-feline immunodeficiency virus and anti-human immunodeficiency virus effect of IFN-tau. J. Immunol. 158 (1997), 4351–4357.
23. Reed, L.J., Muench, H., A simple method of estimating fifty per cent endpoints. Am. J. Hyg. 27 (1938), 493–497.
24. Roberts, R.M., Liu, L., Guo, Q., Leaman, D., Bixby, J., The evolution of the type I interferons. J. Interferon Cytokine Res. 18 (1998), 805–816.
25. Rogez, C., Martin, M., Dereuddre-Bosquet, N., Martal, J., Dormont, D., Clayette, P., Anti-human immunodeficiency virus activity of tau interferon in human macrophages: involvement of cellular factors and beta-chemokines. J. Virol. 77 (2003), 12914–12920.
26. Sadler, A.J., Williams, B.R., Interferon-inducible antiviral effectors. Nat. Rev. Immunol. 8 (2008), 559–568.
27. Samuel, C.E., Antiviral actions of interferons. Clin. Microbiol. Rev. 14 (2001), 778–809 (table of contents).
28. Scudamore, J.M., Harris, D.M., Control of foot and mouth disease: lessons from the experience of the outbreak in Great Britain in 2001. Rev. Sci. Tech. 21 (2002), 699–710.
29. Soos, J.M., Subramaniam, P.S., Hobeika, A.C., Schiffenbauer, J., Johnson, H.M., The IFN pregnancy recognition hormone IFN-tau blocks both development and superantigen reactivation of experimental allergic encephalomyelitis without associated toxicity. J. Immunol. 155 (1995), 2747–2753.
30. Zhu, J., Weiss, M., Grubman, M.J., de los Santos, T., Differential gene expression in bovine cells infected with wild type and leaderless foot-and-mouth disease virus. Virology 404 (2010), 32–40.